Report sees strong year ahead for life sciences IPOs despite headwinds
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As Lisa Suennen said about this year's JP Morgan Healthcare Conference, "There was a lot of optimism about the convergence of biotech, life sciences and health IT, but also there was a sense of foreboding that the party is over in some of these areas."
This week we will be looking back at 2016 JP Morgan Healthcare Conference: what was said, the big news and what it means for the business of healthcare going forward.